Lead Product(s): SPVN06
Therapeutic Area: Genetic Disease Product Name: SPVN06
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: 4BIO Capital
Deal Size: $51.9 million Upfront Cash: Undisclosed
Deal Type: Financing October 21, 2020
Proceeds from the financing will be primarily used to advance the development of SparingVision’s breakthrough treatment SPVN06 for the mutation-agnostic treatment of retinitis pigmentosa.